DYRK2高表达介导结直肠癌奥沙利铂耐药  

High DYRK2 expression mediates oxaliplatin resistance in colorectal cancer

作　　者：陈颖[1,2] 杨博文 包博文[1,2] 李智 车晓芳 CHEN Ying;YANG Bowen;BAO Bowen;LI Zhi;CHE Xiaofang(Department of Medical Oncology,The First Hospital of China Medical University,Shenyang 110001,China;Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province,The First Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院肿瘤内科,沈阳110001 [2]辽宁省抗肿瘤药物与生物治疗重点实验室,沈阳110001

出　　处：《中国医科大学学报》2021年第5期429-434,共6页Journal of China Medical University

基　　金：辽宁省重点研发指导计划(2018225060);沈阳市科学技术计划(2019-ZD-0777)。

摘　　要：目的探讨肠癌奥沙利铂疗效的预测因子。方法按照入组条件筛选基因表达数据库(GEO),与人类癌细胞系(NCI60)数据库奥沙利铂相关基因取交集,得到双特异性酪氨酸磷酸化调节激酶(DYRK2)。细胞毒性试验(MTT)验证了敲减DYRK2后HCC116和Caco2两株肠癌细胞系对奥沙利铂敏感性增加。后续应用蛋白相互作用网络(String)数据库找到与DYRK2相关的蛋白,功能富集分析数据库DAVID和Metascape进行在线通路富集分析。结果DYRK2敲减后HCC116和Caco2两株肠癌细胞系对奥沙利铂敏感性增加。DYRK2可能与肿瘤抑制蛋白(TP53蛋白)存在相互作用,通过Notch通路发挥奥沙利铂耐药作用。结论DYRK2可能成为肠癌奥沙利铂疗效预测因子。Objective To find predictors of oxaliplatin efficacy in colorectal cancer.Methods The GEO database was screened online according to entry criteria,and oxaliplatin-related genes were used to screen the NCI60 database,yielding bispecific tyrosine phosphorylated regulatory kinase(DYRK2).Sensitivity of HCC116 and Caco2 colorectal cancer cell lines to oxaliplatin after DYRK2 knockout was verified by MTT.The String database was then searched to find DYRK2-related proteins,and DAVID and Metascape were queried for online pathway enrichment analysis.Results After DYRK2 knockdown,oxaliplatin sensitivity increased.DYRK2 may interact with TP53 to impart oxaliplatin resistance through the Notch pathway.Conclusion DYRK2 may be used as a predictor of oxaliplatin efficacy in colorectal cancer.

关 键 词：结直肠癌 奥沙利铂 双特异性酪氨酸磷酸化调节激酶 

分 类 号：R735.3[医药卫生—肿瘤]